REQUEST A DEMO
Total
USD $0.00
Search more companies

Advagene Biopharma Co., Ltd. (昱厚生技股份有限公司) (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Advagene Biopharma Co., Ltd. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

Advagene Biopharma Co., Ltd. is mainly engaged in the development of nasal spray-type influenza vaccines, respiratory allergic treatment vaccines, and other vaccine applications. The company was founded in 2006 and is headquartered in Taipei City, Taiwan.

Headquarters
6F,No 308, Sec.1,Neihu Rd, Niehu Dist
Taipei City; Taipei City;

Contact Details: Purchase the Advagene Biopharma Co., Ltd. (昱厚生技股份有限公司) report to view the information.

Website: http://www.advagene.com.tw

Basic Information
Total Employees:
Purchase the Advagene Biopharma Co., Ltd. (昱厚生技股份有限公司) report to view the information.
Outstanding Shares:
Purchase the Advagene Biopharma Co., Ltd. (昱厚生技股份有限公司) report to view the information.
Financial Auditors:
Purchase the Advagene Biopharma Co., Ltd. (昱厚生技股份有限公司) report to view the information.
Incorporation Date:
September 19, 2006
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
25.42%
Purchase this report to view the information.
4.79%
Purchase this report to view the information.
4.22%
Purchase this report to view the information.
2.58%
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Advagene Biopharma Co., Ltd. (昱厚生技股份有限公司) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
-7.52%
EBITDA
-7.78%
Net Profit (Loss) for the Period
-5.35%
Total assets
55.93%
Total equity
72.68%
Return on Equity (ROE)
11.28%
Debt to Equity Ratio
-3.89%
Quick Ratio
21.32%
Cash Ratio
-0.03%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?